SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Authors
Keywords
-
Journal
Biomedicines
Volume 10, Issue 10, Pages 2458
Publisher
MDPI AG
Online
2022-10-08
DOI
10.3390/biomedicines10102458
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SGLT2 inhibitors and the risk of urinary tract infections in patients with heart failure: A pooled analysis examining safety endpoints
- (2022) Josip A Borovac et al. Kardiologia Polska
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
- (2022) et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Expectations in children with glomerular diseases from SGLT2 inhibitors
- (2022) Luigi Cirillo et al. PEDIATRIC NEPHROLOGY
- Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
- (2022) William V Tamborlane et al. Lancet Diabetes & Endocrinology
- Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
- (2022) Kevin Yau et al. Kidney International Reports
- The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
- (2021) Michelle L. O’Donoghue et al. DIABETOLOGIA
- Comparison of New Oral Hypoglycemic Agents on Risk of Urinary Tract and Genital Infections in Type 2 Diabetes: A Network Meta-analysis
- (2021) Miaoran Wang et al. ADVANCES IN THERAPY
- SGLT2 inhibitors and the risk of diabetic ketoacidosis: A systematic review and meta-analysis
- (2021) Michael Colacci et al. Canadian Journal of Diabetes
- SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
- (2021) Chu Lin et al. Cardiovascular Diabetology
- Safety of four SGLT2 inhibitors in three chronic diseases: A meta-analysis of large randomized trials of SGLT2 inhibitors
- (2021) Mei Qiu et al. Diabetes & Vascular Disease Research
- Clinical Adverse Events Associated with Sodium–Glucose Cotransporter 2 Inhibitors: A Meta-Analysis Involving 10 Randomized Clinical Trials and 71 553 Individuals
- (2021) Donna Shu-Han Lin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
- (2021) Clara García-Carro et al. Frontiers in Medicine
- Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
- (2021) Lauren A. Eberly et al. JAMA Network Open
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients with Heart Failure and a Preserved Ejection Fraction: The EMPEROR-Preserved Trial
- (2021) Milton Packer et al. CIRCULATION
- Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
- (2021) Taha Sen et al. DIABETOLOGIA
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
- (2021) Theresa A McDonagh et al. EUROPEAN HEART JOURNAL
- Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling
- (2021) William Durante et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) as a Primary Preventative Agent in the Healthy Individual: A Need of a Future Randomised Clinical Trial?
- (2021) Dan Xu et al. Frontiers in Medicine
- Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis
- (2021) Yu-Sheng Zhang et al. Frontiers in Endocrinology
- Comprehensive Analysis of Adverse Events Associated With SGLT2is: A Meta-Analysis Involving Nine Large Randomized Trials
- (2021) Mei Qiu et al. Frontiers in Endocrinology
- Incidence and risk factors for mortality and end-stage renal disease in people with type 2 diabetes and diabetic kidney disease: a population-based cohort study in the UK
- (2021) Antonio González-Pérez et al. BMJ Open Diabetes Research & Care
- Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
- (2020) Boris Bikbov et al. LANCET
- Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus
- (2020) Jie Liu et al. CURRENT MEDICAL RESEARCH AND OPINION
- The tubular hypothesis of nephron filtration and diabetic kidney disease
- (2020) Volker Vallon et al. Nature Reviews Nephrology
- Glucose transporters in the kidney in health and disease
- (2020) Volker Vallon PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories – Insights from the EMPA‐REG OUTCOME trial
- (2020) Christoph Wanner et al. DIABETES OBESITY & METABOLISM
- Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
- (2020) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
- (2020) Guntram Schernthaner et al. Cardiovascular Diabetology
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin in Patients with Chronic Kidney Disease
- (2020) Hiddo J.L. Heerspink et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Canagliflozin in Patients with Baseline eGFR
- (2020) George Bakris et al. Clinical Journal of the American Society of Nephrology
- Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
- (2020) Megumi Oshima et al. KIDNEY INTERNATIONAL
- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
- (2020) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis
- (2020) Mei Qiu et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial
- (2020) Bettina J. Kraus et al. KIDNEY INTERNATIONAL
- Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
- (2019) Yangli Ye et al. Frontiers in Pharmacology
- Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
- (2019) Jennifer R Donnan et al. BMJ Open
- Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney
- (2019) Hiddo J L Heerspink NEPHROLOGY DIALYSIS TRANSPLANTATION
- Analysis from the EMPA-REG OUTCOME® trial indicate empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics
- (2019) Gert J. Mayer et al. KIDNEY INTERNATIONAL
- Effect of canagliflozin on the overall clinical state including insulin resistance in Japanese patients with type 2 diabetes mellitus
- (2019) Yoko Koike et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis
- (2019) Tadashi Toyama et al. DIABETES OBESITY & METABOLISM
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
- (2019) Chiara Maria Assunta Cefalo et al. Cardiovascular Diabetology
- A safety update on sodium glucose co‐transporter 2 inhibitors
- (2019) David Fitchett DIABETES OBESITY & METABOLISM
- Acute kidney injury with sodium‐glucose co‐transporter‐2 inhibitors: A meta‐analysis of cardiovascular outcome trials
- (2019) Richard E. Gilbert et al. DIABETES OBESITY & METABOLISM
- Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
- (2019) Hiddo J. L. Heerspink et al. DIABETOLOGIA
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sodium–Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections
- (2019) Chintan V. Dave et al. ANNALS OF INTERNAL MEDICINE
- Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
- (2019) André J. Scheen Current Cardiology Reports
- Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents
- (2019) Boris Fishman et al. Cardiovascular Diabetology
- Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men
- (2019) Karin Rådholm et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Appraisal of Non-Cardiovascular Safety for Sodium–Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials
- (2019) Fang-Hong Shi et al. Frontiers in Pharmacology
- SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis
- (2019) Brendon L Neuen et al. Lancet Diabetes & Endocrinology
- Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease
- (2019) C. David Mazer et al. CIRCULATION
- The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
- (2019) Erik J.M. van Bommel et al. KIDNEY INTERNATIONAL
- SGLT2 inhibitors and urinary tract infections
- (2019) John Wilding Nature Reviews Endocrinology
- Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program
- (2018) Brendon L. Neuen et al. CIRCULATION
- SGLT2 inhibition and kidney protection
- (2018) Josselin Nespoux et al. CLINICAL SCIENCE
- Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
- (2018) Claire C. J. Dekkers et al. DIABETES OBESITY & METABOLISM
- Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
- (2018) Chiara Ghezzi et al. DIABETOLOGIA
- Development of SGLT1 and SGLT2 inhibitors
- (2018) Timo Rieg et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- Obesity-associated glomerular inflammation increases albuminuria without renal histological changes
- (2018) Akira Mima et al. FEBS Open Bio
- Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
- (2018) Vlado Perkovic et al. Lancet Diabetes & Endocrinology
- Mechanism of Increased LDL (Low-Density Lipoprotein) and Decreased Triglycerides With SGLT2 (Sodium-Glucose Cotransporter 2) Inhibition
- (2018) Debapriya Basu et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
- (2018) Ningning Wan et al. Frontiers in Endocrinology
- The renoprotective effects of sodium-glucose cotransporter 2 inhibitors versus placebo in patients with type 2 diabetes with or without prevalent kidney disease: A systematic review and meta-analysis
- (2018) Chen Wang et al. DIABETES OBESITY & METABOLISM
- Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers
- (2018) Hiddo J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
- (2017) Lennart Tonneijck et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
- (2017) David Z I Cherney et al. Lancet Diabetes & Endocrinology
- Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
- (2017) Christoph Wanner et al. CIRCULATION
- Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis
- (2017) Jiali Liu et al. Scientific Reports
- Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers
- (2016) H. J. L. Heerspink et al. DIABETES OBESITY & METABOLISM
- The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
- (2016) David Cherney et al. DIABETOLOGIA
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
- (2016) Hiddo J. L. Heerspink et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015
- (2016) Theo Vos et al. LANCET
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β -cell function and reduction of insulin resistance
- (2016) Hideaki Kaneto et al. Journal of Diabetes
- Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
- (2016) Linda A. Gallo et al. Scientific Reports
- The impact of hyperfiltration on the diabetic kidney
- (2015) E. Premaratne et al. DIABETES & METABOLISM
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Tofogliflozin, A Highly Selective Inhibitor of SGLT2 Blocks Proinflammatory and Proapoptotic Effects of Glucose Overload on Proximal Tubular Cells Partly by Suppressing Oxidative Stress Generation
- (2015) Y. Ishibashi et al. HORMONE AND METABOLIC RESEARCH
- Empagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2 Exerts Anti-Inflammatory and Antifibrotic Effects on Experimental Diabetic Nephropathy Partly by Suppressing AGEs-Receptor Axis
- (2015) A. Ojima et al. HORMONE AND METABOLIC RESEARCH
- Spotlight on CKD deaths—increasing mortality worldwide
- (2015) Connie M. Rhee et al. Nature Reviews Nephrology
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
- (2014) T. D. Pessoa et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart
- (2014) Ivana Vrhovac et al. PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY
- Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
- (2014) Naoto Terami et al. PLoS One
- Inhibition of sodium-linked glucose reabsorption normalizes diabetes-induced glomerular hyperfiltration in conscious adenosine A1-receptor deficient mice
- (2013) J. Sällström et al. Acta Physiologica
- Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
- (2013) H. J. Lambers Heerspink et al. DIABETES OBESITY & METABOLISM
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control
- (2013) Donald E. Kohan et al. KIDNEY INTERNATIONAL
- Canagliflozin: Effects in overweight and obese subjects without diabetes mellitus
- (2013) Harold E. Bays et al. Obesity
- Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
- (2013) Usha Panchapakesan et al. PLoS One
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion
- (2011) V. Gorboulev et al. DIABETES
- SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
- (2011) Michael J. Jurczak et al. DIABETES
- Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
- (2009) J. E. Gerich DIABETIC MEDICINE
- Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics
- (2008) Leon G. Fine et al. KIDNEY INTERNATIONAL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started